Chemomab Therapeutics Valuation
| CMMB Stock | USD 0.59 0.07 10.61% |
Chemomab Therapeutics is undervalued. Chemomab Therapeutics shows a prevailing Real Value of $2.18 per share. The current price of the firm is $0.59. Our model approximates the value of Chemomab Therapeutics from analyzing the firm fundamentals such as return on equity of -0.91, and Current Valuation of 168.31 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend. Key fundamental drivers impacting Chemomab Therapeutics' valuation include:
Price Book 0.6433 | Enterprise Value 168.3 M | Enterprise Value Ebitda 0.3331 | Forward PE 13.0039 |
Undervalued
Today
Please note that Chemomab Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Chemomab Therapeutics is based on 3 months time horizon. Increasing Chemomab Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Chemomab Therapeutics Ltd is useful when determining the fair value of the Chemomab stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Chemomab Therapeutics. Since Chemomab Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Chemomab Stock. However, Chemomab Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.59 | Real 2.18 | Target 7.0 | Hype 0.59 | Naive 0.58 |
The real value of Chemomab Stock, also known as its intrinsic value, is the underlying worth of Chemomab Therapeutics Company, which is reflected in its stock price. It is based on Chemomab Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Chemomab Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Chemomab Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Chemomab Therapeutics Ltd helps investors to forecast how Chemomab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Chemomab Therapeutics more accurately as focusing exclusively on Chemomab Therapeutics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Chemomab Therapeutics' intrinsic value based on its ongoing forecasts of Chemomab Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Chemomab Therapeutics' closest peers. When choosing an evaluation method for Chemomab Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Chemomab Therapeutics Investments |
|
Chemomab Valuation Trend
Knowing Chemomab Therapeutics' actual value is paramount for traders to make sound investment determinations. Chemomab Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Chemomab Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Chemomab Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Chemomab Market Cap
Chemomab Therapeutics Ltd is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 2.22 Billion. Chemomab Therapeutics adds roughly 9.39 Million in market capitalization claiming only tiny portion of equities under Health Care industry.Chemomab Therapeutics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Chemomab Therapeutics's current stock value. Our valuation model uses many indicators to compare Chemomab Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chemomab Therapeutics competition to find correlations between indicators driving Chemomab Therapeutics's intrinsic value. More Info.Chemomab Therapeutics Ltd is rated below average in price to book category among related companies. It is rated below average in beta category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Chemomab Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Chemomab Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chemomab Therapeutics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Chemomab Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Chemomab Therapeutics and how it compares across the competition.
About Chemomab Therapeutics Valuation
The stock valuation mechanism determines the current worth of Chemomab Therapeutics Ltd on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Chemomab Therapeutics Ltd. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Chemomab Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Chemomab Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Chemomab Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Chemomab Therapeutics. We calculate exposure to Chemomab Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Chemomab Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -66.8 K | -70.2 K | |
| Pretax Profit Margin | 0.00 | 0.00 | |
| Operating Profit Margin | 0.00 | 0.00 | |
| Net Profit Margin | 0.00 | 0.00 | |
| Gross Profit Margin | 0.00 | 0.00 |
8 Steps to conduct Chemomab Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Chemomab Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Chemomab Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Chemomab Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Chemomab Therapeutics' revenue streams: Identify Chemomab Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Chemomab Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Chemomab Therapeutics' growth potential: Evaluate Chemomab Therapeutics' management, business model, and growth potential.
- Determine Chemomab Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Chemomab Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Chemomab Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Chemomab Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 11.7 M | |
| Forward Price Earnings | 13.0039 |
Chemomab Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Chemomab Therapeutics Ltd and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Chemomab we look at many different elements of the entity such as Chemomab's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Chemomab Therapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Chemomab Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Chemomab Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Chemomab Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Chemomab Therapeutics' worth.When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemomab Therapeutics Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Chemomab Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.06) | Return On Assets (0.49) | Return On Equity (0.91) |
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.